Literature DB >> 22032627

Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo.

K Ezzedine1, A Diallo, C Léauté-Labrèze, J Séneschal, S Prey, F Ballanger, K Alghamdi, M Cario-André, T Jouary, Y Gauthier, A Taieb.   

Abstract

BACKGROUND: Until now, segmental vitiligo has been considered as a stable entity and mixed vitiligo, the association of segmental and nonsegmental vitiligo, has been reported rarely.
OBJECTIVES: The aim of this study was to search for factors associated with the generalization of vitiligo in patients with segmental vitiligo. PATIENTS AND METHODS: This was a prospective observational study conducted in the vitiligo clinic of the Department of Dermatology of Bordeaux, France. The Vitiligo European Task Force questionnaire was completed for each patient attending the clinic with a confirmed diagnosis of segmental vitiligo after exclusion of other forms of vitiligo (focal, mucosal, not classifiable.) Thyroid function and antithyroid antibodies were screened if not obtained in the previous year.
RESULTS: One hundred and twenty-seven patients were recruited: 101 had segmental vitiligo and 26 had segmental vitiligo that evolved into mixed vitiligo; 56 were male and 71 were female. Most patients had onset of segmental vitiligo before the age of 18. When conducting multivariate analysis, we found the following to be independent factors associated with the evolution of patients' disease from segmental vitiligo to mixed vitiligo: initial percentage of body surface involvement of the segment >1% [odds ratio (OR) 15·14, P=0·002], the presence of halo naevi (OR 24·82, P=0·0001) and leukotrichia (OR 25·73, P=0·0009).
CONCLUSIONS: Halo naevi association and leukotrichia at first consultation in segmental vitiligo are risk factors for the progression of segmental vitiligo to mixed vitiligo. In addition, this progression of segmental vitiligo to mixed vitiligo carries a stronger link if initial segmental involvement is situated on the trunk.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2012        PMID: 22032627     DOI: 10.1111/j.1365-2133.2011.10709.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

2.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Authors:  K Ezzedine; H W Lim; T Suzuki; I Katayama; I Hamzavi; C C E Lan; B K Goh; T Anbar; C Silva de Castro; A Y Lee; D Parsad; N van Geel; I C Le Poole; N Oiso; L Benzekri; R Spritz; Y Gauthier; S K Hann; M Picardo; A Taieb
Journal:  Pigment Cell Melanoma Res       Date:  2012-05       Impact factor: 4.693

3.  Anti-thyroid peroxidase antibody in vitiligo: a prevalence study.

Authors:  R Dash; A Mohapatra; B S Manjunathswamy
Journal:  J Thyroid Res       Date:  2015-01-11

4.  Transcriptome Analysis Reveals the Molecular Immunological Characteristics of Lesions in Patients with Halo Nevi When Compared to Stable Vitiligo, Normal Nevocytic Nevi and Cutaneous Melanoma.

Authors:  Chun Pan; Jingzhe Shang; Haiqin Jiang; Ying Shi; Wenyue Zhang; Jingshu Xiong; Youming Mei; Siyu Long; Gai Ge; Zhenzhen Wang; Ziwei Wu; Hongsheng Wang; Aiping Wu
Journal:  J Inflamm Res       Date:  2021-08-24

Review 5.  Autoimmunity in Segmental Vitiligo.

Authors:  Reinhart Speeckaert; Jo Lambert; Vedrana Bulat; Arno Belpaire; Marijn Speeckaert; Nanja van Geel
Journal:  Front Immunol       Date:  2020-10-27       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.